continu invest busi led growth
recommend buy rate agil along tp
deriv tp base forward price-to-earnings multipl
adjust ep provid
upsid potenti estim
top line growth
estim base follow factor double-digit
growth pharma environment forens continu
strength chemic energi busi strong double-digit
growth china growth across segment
acquisit made
agil report strong result quarter
year well due growth end-market strong growth
china agil revenu increas
increas agil beat
revenu estim
net incom declin
impact discret tax charg relat
enact tax act pass decemb
non-gaap net incom increas
gaap ep declin non-gaap ep
increas adjust oper
margin agil beat adjust ep
estim
mn except ep
compani name inc tickerastock ratingbuyunchangedindustri viewoverweightpositivepric jan week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth inc| januari
incom statement
result revenu
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
agil saw double-digit end-market growth pharma
environment forens along continu strength
chemic energi busi pharma
revenu grew broad-bas strength across
segment region
chemic revenu increas due
balanc gain lsag acg due strength
geograph china busi grew
quarter agil china team deliv
double-digit growth achiev major mileston
cross busi first time
chemic imag system breakthrough chemic
imag spectral analysi
agil acquir develop cutting-
edg cell analysi instrument enabl agil provid
comprehens product portfolio
agil expect revenu rang
repres growth
non-gaap ep expect rang
current price-to-earnings averag price-to-earnings
due declin stock price price-to-earnings
trail
expect forward price-to-earnings multipl
recommend buy rate agil maintain
tp stock price declin
howev fundament agil perform
per expect
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short short share short prior month error dividend split forward annual dividend forward annual dividend trail annual dividend trail annual dividend year averag dividend pay-out dividend date jan ex-dividend date dec last split factor new per last split date inform agil technolog inc| januari
incom statement
result revenu
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
non- reconcili refer page
incom statement revenu total gross research sale gener total oper oper interest incom incom provis incom net incom continu net incom discontinu net incom avail common weight averag share estim annual actual annual actual quarterli inc| januari
 market account receivable- total prepaid expenses- current total current build machineri furnitur total fix non-curr defer incom taxes- non-curr total non-curr total equiti liabilitiesaccount accru defer current liabilities- total current long-term defer incom non-curr minor interest total non-curr liabilities- total liabilities- prefer stock equity- common stock addit paid-in retain treasuri stock- total total total liabil stock actual annual actual quarterli balanc sheet item agil inc| januari
net cash provid oper activ compar agil
paid variabl incent pay program
net cash use invest activ compar
invest properti plant equip
net cash use financ activ compar
depreciation- defer incom oper increas decreas increas decreas current assets- decreas increas decreas increas current liabilities- decreas increas work non- net continu net discontinu operations- net total oper invest activitiessal properti plant purchas properti plant net invest financ activitiesissu issuanc capit stock- repurchas capit payment financ charg discontinu financ activities- net financ net floweffect exchang rate net chang begin end inc| januari
agil deliv strong perform quarter due double-digit
growth end-market pharma environment forens along
continu strength chemic energi busi
increas
due
strong growth
forens chemic
china
agil revenu increas compar
due strong growth pharma environment forens
chemic china market
cog increas compar
gross margin increas slightli compar
adjust gross margin increas
compar
 expens increas compar
sg expens increas
compar
oper incom increas compar
oper margin compar
adjust oper margin
compar
gaap ep increas
compar
interest incom compar
interest expens compar
tax rate compar
net incom increas compar
adjust net incom increas
compar
gaap ep increas compar
non-gaap ep increas compar
agil
double-digit growth
mileston cross
busi
revenu geographi
 contribut total revenu
europ contribut total revenu
asia pacif region contribut total revenu
china busi grew quarter agil china
team deliv double-digit growth achiev major mileston
cross busi first time asia japan grew
europ america solid mid-single-digit growth
revenu type instrument revenu quarter contribut
total revenu consum servic informat contribut total
revenu
revenu major market analyt laboratori contribut total
revenu dx clinic market contribut total revenu
net revenu increas compar
foreign currenc movement favor impact ppt
net product revenu increas compar
compar
servic revenu increas compar
servic revenu increas major servic
categori within agil crosslab busi servic diagnost
genom busi increas due growth genom patholog
increas
compar
cog increas compar
gross margin increas compar
manufactur materi cost lower amort expens intang
asset partial off-set increas wage variabl pay impair
certain intang asset unfavor currenc movement
 expens increas compar
 expens increas due increas program spend
new product relat busi addit higher wage
variabl pay unfavor currenc movement addit expens relat
acquir busi
sg expens increas compar
sg expens increas due higher wage variabl pay
compens expens higher transform initi cost impair
certain intang asset unfavor currenc movement
oper incom increas compar
oper margin increas slightli
compar oper margin impact higher
gross margin lower acquisit integr cost lower amort
interest incom increas compar
interest expens decreas compar
interest expens relat interest charg senior note
amort defer loss record upon termin
incom increas compar
effect tax rate compar
effect tax rate result provis incom tax
significantli impact discret charg relat
enact tax job act
net incom declin compar net
incom net incom impact discret tax charg
relat enact tax act pass decemb
non-gaap net incom increas
compar
gaap ep declin compar
non-gaap ep increas compar
agil acquir seven busi combin purchas price
largest advanc analyt technolog inc
cash novemb agil acquir stock
acea bioscienc inc develop cell analysi tool cash
agil acquir two busi combin purchas price
net incom declin
compar net
incom
compar
revenu end-market
agil strong growth quarter due gain pharma
revenu grew
broad-bas
strength across
segment region
revenu increas
broad-bas
strength cobalt
raman spectroscopi
environment lc-
ms icp-m
grew y/i core basi
pharma revenu grew broad-bas strength
across segment region growth balanc bio-
pharma small molecul applic
academia government revenu increas fund stabil
driven strong result china lc lc-m
environment forens revenu increas broad-bas
growth forens saw strength cobalt raman spectroscopi
environment lc-m icp-m
food flat tough compar anticip slow china
chemic increas due balanc gain lsag
acg due strength spectroscopi lc-m suppli servic
diagnost clinic end market revenu grew y/i core basi
due strong growth genom off-set soft pain manag
instrument difficult compar patholog
chemic forens clinic govern inc| januari
life scienc appli market group lsag
life scienc appli market busi provid application-focus
solut includ instrument softwar enabl custom
identifi quantifi analyz physic biolog properti
substanc product well enabl custom clinic life
scienc research area interrog sampl molecular cellular
lsag revenu increas compar
total revenu increas
compar foreign currenc movement overal
favor impact revenu ppt
perform within life scienc appli market busi
led strong growth throughout year pharmaceut market
chemic energi market environment forens market
continu show strong growth
gross margin increas compar
gross margin increas compar
compar
increas
compar
incom oper increas compar
incom oper increas
compar
oper margin increas compar
oper margin increas compar
breakthrough chemic imag spectral analysi
acquir acea bioscienc develop cutting-edg cell analysi
instrument enabl agil provid comprehens product
agil crosslab busi span entir lab extens consum
servic portfolio design improv custom outcom
product categori consum includ gc lc column sampl
prepar product custom chemistri larg select laboratori
instrument suppli servic includ start-up oper train
complianc support softwar servic well asset manag
consult servic help increas custom product
agil crosslab group revenu increas
compar total revenu increas
compar foreign currenc
movement overal favor impact revenu ppt
perform agil crosslab busi saw continu growth
key end market strong growth pharmaceut food
revenu increas
compar
introduc
advantag hplc
uhplc instrument
gross margin increas compar
gross margin increas compar
incom oper increas compar
incom oper increas
compar
oper margin increas compar
oper margin increas compar
acquir agilent-rel busi young scientif co long-
time distributor enabl expand servic capabl fast-grow
introduc infinitylab poroshel chiral column offer signific
speed advantag hplc uhplc instrument
diagnost genom group dgg
diagnost genom busi includ genom nucleic acid contract
manufactur patholog companion diagnost reagent
partnership busi compris five area activ provid
solut includ reagent instrument softwar consum
enabl custom clinic life scienc research area interrog
sampl cellular molecular level
dcg revenu increas compar
total revenu increas
compar foreign currenc movement
overal favor impact revenu ppt
perform within diagnost genom busi led
strong growth genom companion diagnost biomolecular
gross margin increas compar
gross margin increas compar
compar
agil select
unilab one
provid europ
prefer
patholog
incom oper increas compar
incom oper increas
compar
oper margin increas compar
oper margin decreas compar
agil select unilab one largest diagnost
provid europ prefer patholog busi
 fda approv agil dako pharmdx assay
expand use urotheli carcinoma
agil recent action profit growth plan includ
deliv agil agil initi
multi-year program increas effici custom focu
adjust oper margin expand
portfolio invest go-to-market capabl
acquir acea bioscienc develop cutting-edg cell analysi
instrument enabl agil provid comprehens product
acquir prozym lead provid biopharma consum
glycan analysi strengthen agil offer applic space
essenti develop biotherapeut drug
acquir agilent-rel busi young scientif co long-
time distributor fast-grow south korean market
open logist hub qingdao second five plan
locat allow agil deliv part suppli
consum custom laboratori china hour
breakthrough chemic imag spectral analysi
cari uv-vi system first signific advanc uv-
vi architectur decad
agil icp-m analyz enabl environment
laboratori implement water-test method day rather
cutting-edg cell
enabl agil
provid
acquir agilent-
relat busi
long-tim distributor
fast-grow south
revenu expect rang
adjust ep expect rang
dilut share count remain
revenu expect rang
adjust ep expect rang
adopt pension account chang result bp y/i
reduct om off-set income/expens net impact
net interest income/expens net expens
inclus keysight bill impact
sharehold return dividend novemb author
repurchas share depend market condit
revenu expect
rang
revenu expect
rang
adjust ep expect
rang
adjust ep
expect rang
agil report strong result year growth revenu
due growth led china pharma environment forens end
market agil revenu increas
net incom declin impact
discret tax charg relat enact tax act pass
decemb non-gaap net incom increas
ep declin non- ep
increas
lsag revenu increas increas
perform within life scienc appli market
busi led strong growth throughout year pharmaceut
agil crosslab group revenu increas
increas perform agil crosslab
busi saw continu growth key end market strong growth
pharmaceut food market
dcg revenu increas ad increas
perform within diagnost genom
busi led strong growth genom companion diagnost
agil strengthen molecular spectroscopi portfolio launch
agil laser direct infrar chemic imag agil
acquir develop cutting-edg cell analysi
instrument enabl agil provid comprehens product
portfolio agil complet acquisit prozym expand offer
biopharma marketplac
agil continu invest growth introduc new
differenti product servic agil achiev highest annual core
growth rate profit sinc becom stand-alon life scienc
compani
result year
growth
revenu due growth
led china pharma
environment
agil achiev
growth rate
life scienc compani
non- reconcili
non- reconcili
non- reconcili
incom statement
result revenu
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
gross margin increas compar due declin cog
revenu growth increas compar
net margin reduc compar due increas tax
ep growth reduc compar
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth agil inc| januari
mrqgross mrqoper mrqnet mrqcog mrqsg mrqr sale agil inc| januari
invest flow
sale
mrqfinanci mrqreturn mrqreturn mrqyoy growth revenu growthoper incom growthep mrq ratio growth yoy oper growth yoy free growth mrqcapex salescap ex salesfre /sale agil inc| januari
per share item ratio
fiscal per ebitda per ebit per earn per share ep ep free flow per dividend per book valu per tangibl book per month end stock month end stock equiti return asset return invest capit return capit joel greenblatt debt gross margin oper margin net margin total equiti total lt debt total asset dividend pay-out day sale day account day convers inventori cog inventori tax rate net incom net incom net net margin prefer dividends- annual itemsquarterli item agil technolog inc| januari
balanc sheet item
outstand equival market debt common prefer stock- purchas properti plant sale properti plant purchas sale purchas investment- sale investment- issuanc stock- repurchas net issuanc prefer stock- net issuanc debt- net chang capit free inc| januari
current price-to-earnings averag price-to-earnings due declin stock price price-to-earnings
trail expect forward price-to-earnings multipl
incom statement
result revenu
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
breakdown share held share held float held institut hold institut holdersholdersharesd report outvaluepric row associ vanguard group inc fmr oppenheim fund shaw co state mutual automobil insur primecap manag top mutual fund holdersholdersharesd report outvaluevanguard total stock market price row mid cap growth vanguard price row price row valu spdr etf vanguard institut fund-institut vanguard growth fidel ishar inc| januari
developmentsagil complet acquisit acea biosciencesnovemb inc announc complet acquisit acea bioscienc inc acea develop cutting-edg cell analysi tool cash acquisit bring togeth two pioneer cellular function metabol measur focus real-tim live cell analys agil introduc new icp-m analyz solutionnovemb inc introduc new turnkey solut analyz water qualiti theagil icp-m analyzeren environment laboratori set run regul method matter day rather week even month new water analyz packag repres end-to-end workflow analyz water qualiti base regul establish environment protect agenc intern organ standard agil introduc groundbreak uv-vi spectrophotomet biomed academ laboratoriesnovemb inc introduc cari uv-vi system innov spectrophotomet design help life scienc pharma biopharma research commun simplifi analys optim laboratori product ultim help bring new therapeut market faster agil introduc uniqu gener sequencing-bas preimplant genet test pgt solutionoctob inc announc introduct agil onepgt genome-wid next-gener sequenc solut preimplant genet test pgt onepgt allow parallel detect multipl monogen disord pgt-m transloc pgt-sr aneuploidi pgt-a singl biopsi inc| januari
incom statement
result revenu
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
agil
compar
roa roi roe
ttm
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit agil inc| januari
consensu view analyst trend stock
forecast agil
compar
 average
forward price-to-earnings
compar
annual usdgrowth high day day day estim avgfive-year growth forecast comparisonaindustri avg avgprice/earn yield inc| januari
consensu view analyst trend stock
averag revenu estim
current qtr next
qtr
sale growth estim current
qtr next
qtr
averag revenu estim
estimatescurr analyst estimatethi estim estimatepast ep growthprice/earningsobsoleteobsoleteobsoleteobsoletepeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep last last last dayserrorerrorerrorerrordown last dayscurr surprisescurr growth rate agil technolog inc| januari
price target summarycrispidea suissedowngradeneutralund robinson co downgrademarket performrecommend trendscurr monthlast monthtwo month agothre month agostrong estcurr qtr next qtrcurrent yearnext estcurr qtr next qtrcurrent yearnext agil inc| januari
incom statement
result revenu
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
stock price show huge fluctuat period surg decemb
later declin end decemb
averag volum trade quarter stock price declin
period
stock price volatil year declin
rang stock stock surg januari
later show huge fluctuat current trade
stock price show upward trend past gave return past
stock gave huge return past due perform growth past
agil deliv strong result year growth revenu growth adjust
ep total revenu adjust ep growth led end-
market growth pharma environment forens growth china well expect tp
reach
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host client
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com contact
